A password will be e-mailed to you.

Ketamine May Help Treat Pain in Migraine Sufferers Unresponsive to Other Treatments

Summary: Researchers report ketamine may help to relieve pain symptoms associated with migraine in patients for whom other treatments have failed.

Source: ASA.

Ketamine, a medication commonly used for pain relief and increasingly used for depression, may help alleviate migraine pain in patients who have not been helped by other treatments, suggests a study being presented at the ANESTHESIOLOGY 2017 annual meeting.

The study of 61 patients found that almost 75 percent experienced an improvement in their migraine intensity after a three- to seven-day course of inpatient treatment with ketamine. The drug is used to induce general anesthesia but also provides powerful pain control for patients with many painful conditions in lower doses than its anesthetic use.

“Ketamine may hold promise as a treatment for migraine headaches in patients who have failed other treatments,” said study co-author Eric Schwenk, M.D., director of orthopedic anesthesia at Thomas Jefferson University Hospital in Philadelphia. “Our study focused only on short-term relief, but it is encouraging that this treatment might have the potential to help patients long-term. Our work provides the basis for future, prospective studies that involve larger numbers of patients.”

An estimated 12 percent of the U.S. population suffers from migraines – recurring attacks of throbbing or pulsing moderate to severe pain. A subset of these patients, along with those who suffer from other types of headaches, do not respond to treatment. During a migraine, people are often very sensitive to light, sound and may become nauseated or vomit. Migraines are three times more common in women than in men.

The researchers reviewed data for patients who received ketamine infusions for intractable migraine headaches – migraines that have failed all other therapies. On a scale of 0-10, the average migraine headache pain rating at admission was 7.5, compared with 3.4 on discharge. The average length of infusion was 5.1 days, and the day of lowest pain ratings was day 4. Adverse effects were generally mild.

Dr. Schwenk said while his hospital uses ketamine to treat intractable migraines, the treatment is not yet widely available. Thomas Jefferson University Hospital will be opening a new infusion center this fall that will treat more patients with headaches using ketamine. “We hope to expand its use to both more patients and more conditions in the future,” he said.

Image shows a woman holding her head.

An estimated 12 percent of the U.S. population suffers from migraines – recurring attacks of throbbing or pulsing moderate to severe pain. NeuroscienceNews.com image is in the public domain.

“Due to the retrospective nature of the study, we cannot definitively say that ketamine is entirely responsible for the pain relief, but we have provided a basis for additional larger studies to be undertaken,” Dr. Schwenk added.

About this neuroscience research article

Source: ASA
Publisher: Organized by NeuroscienceNews.com.
Image Source: NeuroscienceNews.com image is in the public domain.

Cite This NeuroscienceNews.com Article
ASA “Ketamine May Help Treat Pain in Migraine Sufferers Unresponsive to Other Treatments.” NeuroscienceNews. NeuroscienceNews, 22 October 2017.
<http://neurosciencenews.com/migraine-pain-ketamine-7787/>.
ASA (2017, October 22). Ketamine May Help Treat Pain in Migraine Sufferers Unresponsive to Other Treatments. NeuroscienceNews. Retrieved October 22, 2017 from http://neurosciencenews.com/migraine-pain-ketamine-7787/
ASA “Ketamine May Help Treat Pain in Migraine Sufferers Unresponsive to Other Treatments.” http://neurosciencenews.com/migraine-pain-ketamine-7787/ (accessed October 22, 2017).
Feel free to share this Neuroscience News.
Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive the latest neuroscience headlines and summaries sent to your email daily from NeuroscienceNews.com
We hate spam and only use your email to contact you about newsletters. We do not sell email addresses. You can cancel your subscription any time.
No more articles